ERBB2 and triple-negative breast carcinoma: Moreover, this novel oncolytic virus selectively kills tumor cells and simultaneously releases IL-15, as well as enhancing the inhibitory effect on breast cancer, even on triple negative breast cancer which tests negative for estrogen receptors, progesterone receptors, and excess HER2 protein [21].